The lab combines computational and experimental methods to study human tumors as a complex ecosystem in which diverse cancer and non-cancer cells interact and collectively determine tumor biology and response to therapies. Lab researchers leverage single cell technologies, computational approaches and clinical collaborations to analyze the diversity of cells within human tumors. They focus on identifying important tumor subpopulations such as cancer stem cells, drug resistant cells, invasive cells, and immune cells that respond to immunotherapies. They then study their function, regulation, and vulnerabilities, with the ultimate goal of developing better cancer treatments.
Dr. Tirosh completed his PhD in the Department of Molecular Genetics at the Weizmann Institute of Science, where he studied gene expression in yeast.
During his postdoctoral fellowship at the Broad Institute of MIT and Harvard, he pioneered the application of single-cell RNASeq to solid human tumors. Collaborating with clinicians at Boston hospitals, he established a general approach to studying intra-tumor heterogeneity and revealing clinically important subpopulations. His studies showed the ways single-cell genomics offers insights with implications for both targeted and immune therapies.
At the Department of Molecular Cell Biology at Weizmann, Dr. Tirosh’s joint computational and experimental research group studies solid tumors as a complex ecosystem. His work has potential for improvements in cancer research and ultimately cancer therapy.